Decoy Therapeutics 2026 shareholder vote results
Decoy Therapeutics Inc. held its 2026 Annual Meeting of Stockholders on July 14, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Decoy Therapeutics Inc. held its 2026 Annual Meeting of Stockholders on July 14, 2026. As of the May 22, 2026 record date, 531,968 shares of common stock were issued, outstanding and entitled to vote, and 225,548 shares, or 42.4%, were represented in person or by proxy, constituting a quorum.
Stockholders elected three Class II directors to serve until the 2029 annual meeting, approved on a non-binding advisory basis the compensation of the named executive officers, and ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding on record date: 531,968 shares
Shares represented at meeting: 225,548 shares
Quorum percentage: 42.4%
+3 more
6 metrics
Shares outstanding on record date
531,968 shares
Common stock issued and outstanding and entitled to vote as of May 22, 2026
Shares represented at meeting
225,548 shares
Shares present in person or represented by proxy at the 2026 Annual Meeting
Quorum percentage
42.4%
Percentage of entitled shares represented at the Annual Meeting, constituting a quorum
Votes for Patricia Gauthier
23,204
For votes to elect Class II director Patricia Gauthier
Say-on-pay votes for
21,278
For votes on non-binding advisory approval of executive compensation
Auditor ratification votes for
214,341
For votes to ratify Ernst & Young LLP for fiscal year ending December 31, 2026
Key Terms
non-binding advisory vote, broker non-votes, independent registered public accounting firm, quorum, +1 more
5 terms
non-binding advisory vote regulatory
"approved, by non-binding advisory vote, the compensation of the Company’s named executive officers"
A non-binding advisory vote is a shareholder vote that expresses investors’ opinion on a proposal (such as executive pay, corporate policy, or governance practices) but does not legally force the company to act. Think of it like a customer survey: it signals whether owners approve or disapprove and can pressure boards and managers to change course, so investors watch the result as an indicator of governance risk and potential future shifts in company strategy or leadership.
broker non-votes regulatory
"Votes For | | Votes Against | | Abstentions | | Broker Non-Votes 23,204 | | 4,110 | | 12 | | 198,222"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm regulatory
"Ernst & Young LLP as the Company's independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
quorum regulatory
"225,548, or 42.4%, were present in person or represented by proxy, which constituted a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
record date regulatory
"As of May 22, 2026, the record date for the Annual Meeting, there were 531,968 shares"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Decoy Therapeutics (DCOY) stockholders approve at the 2026 Annual Meeting?
Stockholders elected three Class II directors to terms ending at the 2029 annual meeting, approved on a non-binding advisory basis the compensation of named executive officers, and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
What quorum was present at Decoy Therapeutics (DCOY) 2026 Annual Meeting?
Holders of 225,548 shares, representing 42.4% of the shares entitled to vote, were present in person or by proxy. This level of representation constituted a valid quorum for conducting business at the 2026 Annual Meeting.
How did Decoy Therapeutics (DCOY) stockholders vote on executive compensation?
In the advisory say-on-pay proposal, stockholders cast 21,278 votes for, 5,041 against and 1,007 abstentions, with 198,222 broker non-votes, approving on a non-binding advisory basis the compensation of the company’s named executive officers.
What were the vote results for Decoy Therapeutics (DCOY) auditor ratification?
Stockholders voted 214,341 shares for, 9,584 against and 1,623 abstaining to ratify the appointment of Ernst & Young LLP as Decoy Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026.
How did Decoy Therapeutics (DCOY) director nominees fare in the 2026 election?
Class II director nominees received the following "for" votes: 23,204 for Patricia Gauthier, 22,964 for Jonathan Lieber and 22,690 for Frederick E. Pierce, each with several thousand votes against and substantial broker non-votes, and were elected to serve until the 2029 annual meeting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates